Skip to content
lifestyle.luxedb.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity
September 11, 2026
Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 17, 2026
Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update
August 6, 2026
Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity
August 4, 2026
Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer
July 28, 2026
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer
July 6, 2026
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
May 14, 2026
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
May 13, 2026
Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update
May 12, 2026
Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026
May 5, 2026
1
2
Next Page
→